A family-based clinical series connected exaggerated startle with glycine-receptor variants. Treatment response accompanied genetic and clinical evidence rather than replacing it.
Four patients from two unrelated families had excessive startle, cautious gait, and recurrent falls. Genetic testing identified GLRA1 variants, including a newly described variant.
All four reportedly had substantial improvement in startle episodes with clonazepam. The article also reviewed related cases and possible mechanisms.
Family relationships, phenotype selection, and case reporting limit extrapolation. The study did not randomize clonazepam or compare it with alternatives.
The findings cannot establish that every exaggerated startle or fall is hyperekplexia, nor that benzodiazepine response proves the genotype. A forensic account should retain triggers, examination, EEG or other differential workup, genetic findings, treatment, and follow-up. Symptomatic improvement is meaningful without proving complete cure, absence of adverse effects, or identical benefit in all genetic subtypes.
Original analysis of the supplied journal article, identified as PMC7174104.